BioNTech revenue and financials
$97.64Change from previous close: +0.76%Absolute change: +$0.74
In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- -39.6%
- 2024: -24.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 456 | 208 | 5,371 | 13,577 | 890 | -13.5 | -199 | -58.9 | -52.6 |
| Depreciation and amortization | 383 | 298 | 183 | 123 | — | — | — | — | — |
| Capital expenditure | -175 | -287 | -249 | -329 | -128 | -66.0 | -38.6 | -29.9 | -24.3 |
| Investing cash flow | -2,469 | -2,081 | -6,955 | -35.3 | — | — | — | — | — |
| Financing cash flow | -52.9 | -45.9 | -779 | -1,419 | — | — | — | — | — |
| Dividends paid | — | 0.0 | 0.0 | -484 | 0.0 | 0.0 | — | — | — |
| Share repurchases | 0.0 | 0.0 | -739 | -986 | — | — | — | — | — |
| Debt issued | 6.7 | 0.0 | 0.3 | 0.8 | — | — | — | — | — |
| Debt repaid | -57.6 | -45.9 | -40.4 | -59.9 | — | — | — | — | — |
| Effect of exchange rates | -27.0 | 14.8 | -14.5 | 60.1 | — | — | — | — | — |
| Net change in cash | -2,065 | -1,919 | -2,362 | 12,123 | — | — | — | — | — |
| Free cash flow | -293 | -245 | 4,666 | 13,214 | — | — | — | — | — |